FAP and neoplasm: A manganese porphyrin-based metal-organic framework (Mn-MOF), FAP gene-engineered tumor cell-derived exosome-like nanovesicles (eNVs-FAP), NC06 or the Dihydroartemisinin (DHA) were explored to treatment hypoxic tumors or as the a candidate tumor vaccine, which was designed to reduce the number of MDSCs by targeting ferroptosis [32–37].